Press release
Parkinson's Disease Psychosis Market Size in the 7MM was ~USD 665 million in 2023. It is expected to grow at a significant CAGR, reaching a notable value by the end of 2034
Parkinson's Disease Psychosis Market
Discover which therapies are expected to grab the Parkinson's Disease Psychosis Market Share @ Parkinson's Disease Psychosis Market Outlook- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Parkinson's Disease Psychosis Market Report
• The total diagnosed prevalent cases of Parkinson's disease in the 7MM were 2,718 thousand in 2023 and are expected to increase at a significant CAGR of throughout the forecast period.
• In 2023, Japan contributed 258 thousand diagnosed prevalent cases of Parkinson's disease, representing almost 9% of the total diagnosed prevalence across the 7MM.
• Among the 7MM, EU4 and the UK accounted for nearly 353 thousand diagnosed prevalent cases of PDP, and these cases are expected to increase during the forecast period (2024-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of PDP, with 134 thousand cases, followed by France and Italy in 2023. On the other hand, the UK had the lowest diagnosed prevalent population in EU4 and the UK in 2023.
• In Japan, there were around 74 thousand diagnosed prevalent cases of PDP in 2023. These cases are expected to increase at a significant CAGR.
• The leading Parkinson's Disease Psychosis Companies such as Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd., and others.
• Promising Parkinson's Disease Psychosis Pipeline Therapies such as aripiprazole, pimavanserin tartrate, ACP-103, SEP-363856 and others.
Stay ahead in the Parkinson's Disease Psychosis Therapeutics Market with DelveInsight's Strategic Report @ Parkinson's Disease Psychosis Market Outlook- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Epidemiology Segmentation in the 7MM
• Total Parkinson's Disease Psychosis Diagnosed Prevalent Cases
• Total Parkinson's Disease Psychosis Diagnosed Prevalent Cases
• Total Parkinson's Disease Psychosis Treated Cases
Download the report to understand which factors are driving Parkinson's Disease Psychosis Epidemiology Trends @ Parkinson's Disease Psychosis Prevalence- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Emerging Parkinson's disease Psychosis Drugs
• ENT-012: Enterin Inc.
ENT-012 is undergoing Phase IIa clinical trials to evaluate its efficacy and safety in treating psychosis associated with Parkinson's disease. This phase focuses on assessing the drug's ability to reduce the severity of psychotic symptoms, measured through the Scale for the Assessment of Positive Symptoms (SAPS). Preliminary results suggest that ENT-012 is generally well-tolerated, with side effects similar to those of other SSRIs, such as gastrointestinal disturbances, headaches, and fatigue. The trial is designed to gather more comprehensive data on its impact on patients, and results are expected in the near future.
Parkinson's disease Psychosis Market Outlook
Parkinson's disease Psychosis (PDP) is a complex condition characterized by the emergence of psychotic symptoms, such as hallucinations and delusions, in patients with Parkinson's disease. The treatment landscape for PDP is still evolving, as the interplay between neurodegeneration and psychosis complicates the establishment of standardized treatment protocols. Currently, there are no universally approved therapies specifically for PDP, and management primarily focuses on alleviating symptoms while ensuring the patient's overall well-being.
To learn more about Parkinson's Disease Psychosis treatment guidelines, visit @ Parkinson's Disease Psychosis Treatment Market Landscape- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Therapies and Companies
• Crenolanib: Arog Pharmaceuticals
• TAS-116: Taiho Pharmaceutical
• Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.
Scope of the Parkinson's Disease Psychosis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Parkinson's Disease Psychosis Companies- Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd., and others.
• Parkinson's Disease Psychosis Pipeline Therapies- aripiprazole, pimavanserin tartrate, ACP-103, SEP-363856 and others.
• Parkinson's Disease Psychosis Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and Parkinson's Disease Psychosis emerging therapies
• Parkinson's Disease Psychosis Market Dynamics: Parkinson's Disease Psychosis market drivers and Parkinson's Disease Psychosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Psychosis Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Psychosis Market Access and Reimbursement
Learn more about the FDA-approved drugs for Parkinson's Disease Psychosis @ Drugs for Parkinson's Disease Psychosis Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Parkinson's Disease Psychosis (PDP) Market Overview at a Glance
4. Parkinson's Disease Psychosis Epidemiology and Market Forecast Methodology
5. Parkinson's Disease Psychosis Executive Summary
6. Key Events
7. Parkinson's Disease Psychosis Disease Background and Overview
8. Parkinson's Disease Psychosis Epidemiology and Patient Population
9. Patient Journey
10. Parkinson's Disease Psychosis Emerging Therapies
11. Parkinson's Disease Psychosis Marketed Therapies
12. Parkinson's Disease Psychosis: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Parkinson's Disease Psychosis Unmet Needs
16. Parkinson's Disease Psychosis Market Access and Reimbursement
17. Appendix
18: DelveInsight Capabilities
19: Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Psychosis Market Size in the 7MM was ~USD 665 million in 2023. It is expected to grow at a significant CAGR, reaching a notable value by the end of 2034 here
News-ID: 4490312 • Views: …
More Releases from DelveInsight Business Research LLP
Postoperative Pain Treatment Market Size in the 7MM was ~USD 3000 Million in 202 …
DelveInsight's "Postoperative Pain Drugs Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of postoperative pain, historical and forecasted epidemiology, as well as the postoperative pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Postoperative Pain Market Share @ Postoperative Pain Market Outlook- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Postoperative Pain…
Spastic Cerebral Palsy Therapeutics Market Size in the 7MM is projected to grow …
DelveInsight's "Spastic Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Spastic Cerebral Palsy, historical and forecasted epidemiology as well as the Spastic Cerebral Palsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Spastic Cerebral Palsy Market Share @ Spastic Cerebral Palsy Market Outlook- https://www.delveinsight.com/sample-request/spastic-cerebral-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spastic…
Treatment-Resistant Depression Market Size in the 7MM was ~USD 3,100 million in …
DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of historical and forecasted epidemiology as well as Treatment-Resistant Depression therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Treatment Resistant Depression Market Share @ Treatment Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Treatment Resistant Depression…
Chronic Traumatic Encephalopathy Therapeutics Market Size in the 7MM is projecte …
DelveInsight's "Chronic Traumatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Chronic Traumatic Encephalopathy, historical and forecasted epidemiology as well as the Chronic Traumatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Chronic Traumatic Encephalopathy Market Share @ Chronic Traumatic Encephalopathy Market Outlook- https://www.delveinsight.com/sample-request/chronic-traumatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Chronic…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
